Leadpages vs Unbounce: which one should a research team buy?

In summary

• Unbounce wins if you will run A/B tests: Experiment at $149/mo ($112 annually) is the first tier with unlimited testing, 30,000 traffic, 3 users and 2 domains. Verified 18 August 2026.
• Build at $99/mo ($74) gives unlimited pages and AI copy but no A/B testing; Starter at $29/mo ($22) is 5 pages, 500 traffic and one seat. Annual billing is 25% off.
• Leadpages is cheaper at the entry level and quicker for a straightforward page. We do not publish Leadpages figures because we only quote prices we have read off a vendor pricing page ourselves and can date-stamp.
• The institutional reason to pay more: IRB-approved recruitment copy needs version history, named variants and the ability to freeze a running test mid-flight. That is governance, not marketing.
• Do not buy Unbounce Experiment if the page will see fewer than roughly a thousand visitors a month — you will not reach a readable result, and Build or Leadpages will do the same job for less.

Price versus capability, in one screen

Unbounce pricing verified from the vendor pricing page, 18 August 2026; annual price in brackets. Leadpages pricing is not quoted here — we publish only prices we have read off a vendor page ourselves.

Dimension	What you are deciding	Unbounce	Leadpages
Entry price	—	Starter $29/mo ($22 annual) — 5 pages, 500 traffic, 1 user	Materially cheaper at the entry tier; positioned as the budget builder
Price to unlock A/B testing	—	Experiment $149/mo ($112) — unlimited A/B tests, 30k traffic, 3 users, 2 domains	Split testing is offered, but as a lighter feature rather than the centre of the product
Unlimited pages	—	From Build $99/mo ($74), with 20k traffic and AI copywriting	Available lower down the range — the main cost argument in its favour
Variant naming and version history	—	Strong: variants are first-class objects you can name, pause and compare	Serviceable for a single page; weaker once several approved variants exist
Seats for a study team	—	3 users on Experiment, 5 on Optimize $249/mo ($187)	Fewer seats at comparable spend; expect shared logins on cheap tiers
Traffic-based routing	—	Smart Traffic on Optimize $249/mo ($187), 50k traffic	No equivalent AI routing layer
Where it genuinely wins	—	A recruitment or fundraising page you will iterate over months	One page, one message, live this week, never tested

Both products are page builders, not consent platforms. Neither should be treated as the system of record for identifiable participant data — see the section on forms and PHI below.

You are buying the testing tier, not the builder

Strip the marketing away and both products do the same core job: they let you publish a page that lives outside your institutional CMS, so a study coordinator can change a headline without raising a ticket with a central web team and waiting a fortnight. That publishing independence is the reason research groups buy either tool, and on that measure they are close enough that price should decide.

The divergence is testing. Unbounce gates A/B testing at Experiment, $149/month or $112/month annually, which also carries 30,000 monthly traffic, 3 users and 2 root domains. Everything below it — Build at $99/month ($74) with unlimited pages, 20,000 traffic and AI copywriting, and Starter at $29/month ($22) with 5 pages, 500 traffic and one seat — is a publishing tool. Optimize at $249/month ($187) adds Smart Traffic routing and 50,000 traffic. Annual billing is 25% cheaper across the published tiers. Verified 18 August 2026.

So the real question in front of you is not “Leadpages or Unbounce”. It is “will this page be tested?”. If the answer is no, buy on price and Leadpages usually wins. If the answer is yes, you are comparing Leadpages against Unbounce Experiment specifically, and the comparison stops being about templates and starts being about how the tool handles multiple live versions of an approved page — which is where institutional buyers get bitten.

IRB-approved copy turns version control into a compliance feature

Here is the constraint that makes this comparison different for a research organisation. A study-recruitment page is not free text. The wording that describes the study, the inclusion criteria, the compensation and the contact route is typically reviewed and approved by an ethics committee or IRB before it can be shown to a potential participant. Change the headline and you may have changed approved recruitment material. Run an A/B test and you have, by definition, two versions live at once — and only one of them may be the approved one unless you planned for that.

That single fact converts three otherwise dull features into load-bearing requirements:

• Version history you can point at. When a monitor asks what was on the page in March, you need to answer with the page, not with a screenshot someone happened to take. Unbounce keeps variants as durable, separately addressable objects rather than as an ephemeral experiment state, which is what makes that answer possible.
• Variant naming that matches your protocol. “Variant B” is useless in a submission. “REC-2026-014 v3 amended consent language” is not. Both tools let you rename; the difference is whether the name survives into reporting, so that the test result and the approval reference are the same string.
• The ability to freeze a test mid-flight. Amendments arrive without warning. If the committee withdraws approval for one variant, you need to stop serving that variant today and keep the other running — not pause the campaign, not take the page down, not lose the accumulated data. Being able to pause one variant while the control keeps collecting is the operational difference between a controlled amendment and an outage.

Leadpages will publish and split-test a page perfectly competently. What it is not built around is the idea that one of your two live versions is a regulated artefact. If your recruitment pages go through committee, budget for the tool that treats variants as first-class objects — and read our guide to clinical trial recruitment landing pages before you write any of the copy, because the approval workflow shapes the page structure more than the builder does.

Form handling, and where participant data must not be captured

Both builders will happily put a form on a page and store the submissions. For a conference sign-up or a newsletter, that is fine. For anything that touches health information, it is not, and this is the single most common mistake we see on institutional landing pages.

Treat the landing page as a poster, not as a filing cabinet. The page exists to explain the study and produce an expression of interest. The moment a field invites a diagnosis, a medication, a date of birth combined with a condition, or anything else that would make the submission identifiable health data, the storage location matters more than the page does — and a general-purpose page builder is not where that record should live. Neither Unbounce nor Leadpages is being sold to you as a HIPAA-scoped data platform, and neither should be treated as one on the strength of a sales call.

The pattern that works: keep the landing page fields to a name, a contact route and a single non-clinical qualifier, then hand off to a screening instrument in a system built for it. Our notes on HIPAA-compliant form builders cover that handoff and which vendors will sign a business associate agreement. The question to put to a vendor is not “are you secure” but “will you sign, and for which product” — anyone who answers the first when you asked the second has told you the answer.

There is a practical benefit as well as a compliance one: a short form converts better than a long one, so the compliant design and the effective design point the same way here.

The traffic level below which Unbounce Experiment is not worth it

Unbounce earns its price when A/B testing produces answers, not when it produces noise that looks like answers — and most institutional pages sit in the second category.

The rule of thumb worth holding onto is that you need a few hundred conversions per variant, not a few hundred visitors overall, before a realistic difference between two headlines becomes readable. On a recruitment page converting in the low single digits, that implies several thousand visitors per variant per test. If your page will see fewer than roughly a thousand visitors a month in total, do not buy Experiment. You will run a test, see one variant ahead, stop it early because the study needs an answer, and act on a result that was chance. That is worse than not testing, because it manufactures false confidence and then propagates it into the next campaign.

At that volume the sensible options are Unbounce Build at $99/month ($74 annually) if you want unlimited pages and AI copywriting, Starter at $29/month ($22) if five pages is genuinely enough, or Leadpages if the cheapest competent builder is the whole requirement. Verified 18 August 2026. Spend the difference on getting more of the right traffic to the page instead — the honest version of the argument is set out in our conversion rate optimisation tools guide, which is mostly about why sample size beats tooling.

The threshold flips quickly, though. A multi-site trial running paid recruitment across several regions will clear that bar in a fortnight, and at that point the arithmetic reverses: a modest lift on a page carrying paid traffic repays the gap between Build and Experiment many times over, and guessing at headlines becomes the expensive option.

Where Leadpages is genuinely the better buy

We take a commission if you buy Unbounce through this page, so it matters that we are specific about when not to. Leadpages is the better buy for a straightforward page with no testing programme behind it. It is materially cheaper at the entry level, it gets a competent page live faster, and for a one-off — a symposium registration page, a departmental open day, a survey landing page that runs for six weeks and is then archived — the extra capability in Unbounce is capability you will pay for and never open.

It is also the better buy when the person building the page is not a marketer. Leadpages leans towards guided templates and fewer decisions, which suits a research administrator handed the job on top of everything else; Unbounce offers more layout control and that control has a learning curve.

Do not buy Unbounce if all of the following are true: you need one page rather than a family of them, nobody has committed to running tests, the page will not be reviewed by a committee, and the traffic will be measured in hundreds rather than thousands. In that situation Unbounce Experiment is roughly a hundred dollars a month of unused capability, and the correct answer is Leadpages or Unbounce Starter at $29/month ($22 annually), not the tier we recommend at the top of this page. Verified 18 August 2026.

Where Unbounce reverses that is durability. The “temporary” recruitment page is still live two years later, maintained by someone who was not there when it was built, and named variants, version history and multiple seats are what make it inheritable. For the wider field, see our best landing page builders comparison.

Instapage and Carrd: the two names you are about to google

Anyone comparing these two eventually searches both, so here is where each one beats our pick.

Instapage is the enterprise option, positioned above both Leadpages and Unbounce on price and pitched at teams running personalised page experiences at advertising scale. If your organisation runs a large, continuously funded paid-acquisition programme with a dedicated team behind it, Instapage belongs on the shortlist and may well win. For the typical research group — a handful of pages, one or two people, budget that has to be justified against a grant line — it is more platform than the problem requires. We are not quoting Instapage prices, for the same reason we are not quoting Leadpages prices: we publish figures we have verified on a vendor page, and nothing else.

Carrd is the honest reason a lot of readers need neither product. If what you actually need is one simple page — a study explainer, a single call to action, a contact form, no testing, no campaign — Carrd builds it at a fraction of the cost of anything discussed here. There is no shame in that being the right answer. The test is whether the page has a second version in its future. One page, one version, one purpose: Carrd. A page that will be tested, amended, re-approved and inherited: Unbounce.

The failure mode we see most often is an institution buying the enterprise tool for a Carrd problem, then buying the Carrd-grade tool for a testing problem a year later. Deciding honestly, in advance, whether anyone is accountable for running tests prevents both mistakes.

Running real tests on your recruitment pages?

Unbounce Experiment at $149/month, or $112/month on annual billing, is the first tier with unlimited A/B testing, and includes 30,000 monthly traffic, 3 users and 2 root domains — variants you can name after your approval reference, pause individually and point at during an audit. Build at $99/month ($74) covers unlimited pages without testing, and Starter is $29/month ($22). Annual billing is 25% cheaper across the published tiers. Verified 18 August 2026.

From $29/mo ($22 billed annually)

See Unbounce pricing and annual discount Opens on the vendor’s site · CASRAI referral link

Frequently asked questions

Leadpages vs Unbounce — which should we actually buy?

Buy Unbounce if the page will be A/B tested, amended and inherited by someone else later; Experiment at $149/month ($112 annually) is the first tier with unlimited testing, and it includes 30,000 monthly traffic, 3 users and 2 root domains. Verified 18 August 2026. Buy Leadpages if you need one competent page live quickly, nobody has committed to running tests, and price is the deciding factor — it is materially cheaper at the entry level and we would rather say so than sell you capability you will not open.

What is the cheapest Unbounce plan that lets us run an A/B test?

Experiment, at $149/month or $112/month on annual billing. Neither Starter at $29/month ($22 annually) nor Build at $99/month ($74) includes A/B testing, which is the single most common surprise for buyers who assume the mid tier covers it. Build does give unlimited pages, 20,000 monthly traffic and AI copywriting, so it is the right choice if you want publishing freedom without a testing programme. Optimize at $249/month ($187) adds Smart Traffic routing and 50,000 traffic. Annual billing is 25% cheaper across the published tiers, so if you have already decided, starting on annual is the one genuine saving available today — you can see the current plans and the annual discount through our Unbounce link. Verified 18 August 2026.

Why do you not publish Leadpages or Instapage prices on this page?

Because we only quote prices we have read off the vendor pricing page ourselves and can date-stamp. That rule applies to every competitor we mention. We are comfortable stating positioning anyone can verify in a minute — Leadpages sits below both products at the entry level, Instapage above them — but a figure recalled rather than checked is a guess, and a guess about price is the fastest way to lose a reader about to spend institutional money.

Can we keep an ethics-approved variant running while we pause the other one?

This is the question that should decide the purchase for any team running committee-approved recruitment copy. You need variant-level control: stop serving one version the day an amendment lands, while the control keeps running and collecting, without taking the page down or resetting the experiment. Unbounce treats variants as separately addressable objects you can name and pause individually. Ask any vendor to demonstrate exactly that action on a live test before you sign, rather than accepting a general assurance about version history.

How much traffic do we need before A/B testing is worth paying for?

More than most institutional pages get. The working rule is a few hundred conversions per variant, not per test, before a realistic difference between two headlines is readable — which on a page converting in the low single digits means several thousand visitors per variant. Below roughly a thousand visitors a month in total, do not buy the Experiment tier: you will stop the test early, act on noise, and carry that false conclusion into the next campaign. Build at $99/month ($74 annually) or a cheaper builder is the correct purchase at that volume. Verified 18 August 2026.

Can we collect participant health information on a landing page?

Design so that you do not have to. A landing page is a poster: it explains the study and captures an expression of interest — a name, a contact route, at most one non-clinical qualifier. Anything that makes a submission identifiable health information belongs in a system built to hold it, under an agreement the vendor has signed for that specific product. Neither Unbounce nor Leadpages is sold as a HIPAA-scoped data platform. Move screening to a dedicated instrument and keep the page short — it converts better anyway.

Is there a cheaper option than either of these?

Yes, and for a single page it is often the right one. Carrd builds a simple one-page site for a fraction of the cost of anything discussed here, and if the page has no second version in its future — no test, no amendment, no campaign behind it — neither Leadpages nor Unbounce is justified. The test is whether you expect to change the page in a controlled way over time. If you do, the version history and variant handling are what you are buying, and the cheap option becomes expensive the first time you cannot evidence what was live in a given month.

Related on CASRAI

• Unbounce review: every plan and price
• Clinical trial recruitment landing pages
• Best landing page builders compared
• HIPAA-compliant form builders
• All software reviewed by CASRAI